High-dose chemo with stem cell transplant vs. standard therapy for older adults with CNS lymphoma
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This study compares a high-dose chemotherapy followed by your own stem cell transplant to standard chemo-immunotherapy for older adults with newly diagnosed primary CNS lymphoma. The goal is to see which approach works better and is safer for people over 70.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed aggressive B-cell lymphoma that started in your brain or spinal cord and is not elsewhere in your body.
- You are 70 years or older, or 65–70 and not able to get a more intense treatment program.
- You have at least one tumor that can be measured on a scan.
- Your daily activity level is mostly normal (able to care for yourself, even if you need help sometimes).
- Your kidneys, bone marrow, heart, lungs, and liver are working well enough for the study treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
This trial tests a stem cell transplant with a special chemo combination (TEAM) to see if it can prevent lymphoma from coming back in the brain or spinal cord for people with high-risk non-Hodgkin lymphoma.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.